Yousif Capital Management LLC Has $15.60 Million Stake in CVS Health Corporation $CVS

Key Points

• Yousif Capital Management LLC reduced its stake in CVS Health by 2.5%, now holding 226,123 shares valued at approximately $15.60 million.
• CVS Health has received several rating upgrades from analysts, with Wall Street Zen upgrading the stock from "hold" to "buy" and Wolfe Research increasing the target price from $80 to $85.
• CVS Health announced a quarterly dividend of $0.665 per share, with a dividend yield of 3.4%, to be paid on November 3rd.

Yousif Capital Management LLC decreased its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 226,123 shares of the pharmacy operator's stock after selling 5,711 shares during the quarter. Yousif Capital Management LLC's holdings in CVS Health were worth $15,598,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Hazlett Burt & Watson Inc. lifted its holdings in shares of CVS Health by 10.9% in the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,682 shares of the pharmacy operator's stock worth $117,000 after purchasing an additional 165 shares in the last quarter. SPC Financial Inc. lifted its holdings in shares of CVS Health by 6.8% in the 2nd quarter. SPC Financial Inc. now owns 9,747 shares of the pharmacy operator's stock worth $672,000 after purchasing an additional 622 shares in the last quarter. Means Investment CO. Inc. lifted its holdings in shares of CVS Health by 184.4% in the 2nd quarter. Means Investment CO. Inc. now owns 11,879 shares of the pharmacy operator's stock worth $819,000 after purchasing an additional 7,702 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of CVS Health by 16.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 151,240 shares of the pharmacy operator's stock worth $10,434,000 after purchasing an additional 21,544 shares in the last quarter. Finally, Concurrent Investment Advisors LLC lifted its holdings in shares of CVS Health by 20.6% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 16,193 shares of the pharmacy operator's stock worth $1,117,000 after purchasing an additional 2,771 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of recent research reports. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a report on Sunday, September 21st. Wolfe Research increased their target price on CVS Health from $80.00 to $85.00 and gave the stock an "outperform" rating in a report on Monday, September 22nd. Bernstein Bank dropped their price objective on CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research note on Wednesday, July 16th. Cowen restated a "buy" rating on shares of CVS Health in a research note on Monday, August 4th. Finally, Baird R W upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $79.80.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.22% of the stock is owned by insiders.

CVS Health Price Performance

Shares of NYSE:CVS opened at $77.89 on Monday. The stock has a market cap of $98.79 billion, a PE ratio of 21.76, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $79.20. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock's fifty day simple moving average is $72.28 and its two-hundred day simple moving average is $67.67.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. The company had revenue of $98.92 billion for the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is presently 74.30%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.